Loading Events

« All Events

  • This event has passed.

5th Antibody Industrial Symposium 2017

27/06/2017 - 28/06/2017

antibody_industrial_symposium_2017

The 5th Antibody Industrial Symposium 2017 (AIS2017) congress, organised by the LabEx MAbImprove, Polepharma and MabDesign, offers an ideal conference for scientists, industries, physicians and policy makers to exchange about Antibody-Drug Conjugates (ADCs).

The Scientific committee has set-up an exciting program focusing on the following topic:

“Antibody Drug Conjugates : Design and Development for Therapy and Imaging in and beyond Cancer”, with keynote lectures, pitch talks of new creative projects, and industrial talks from big pharmaceutical companies. Furthermore, it will be possible to set up business meetings during both days, through an online partnering platform.

The topics covered during this meeting are:

  • ADCs, empowering Cancer Therapy,
  • Discovery of novel ADCs targets and formats
  • Accelerate the development of the next-generation of ADCs
  • Challenges in ADCs Developability, scale-up and manufacturing
  • Moving ADCs forward into clinic: safety and efficacy

CALL FOR ABSTRACTS

Share your innovative products, new technologies and research projects at the Pitch Session “New ADC formats – Diagnostics and Imunomonitoring ”! Abstract submission for a pitch talk or for a poster until Wednesday, 15th March 2017.

REGISTER

Early Bird Registration until Friday, 31st March 2017 – register early to secure the best rates! MabDesign and Polepharma members have 20% discount on the registration fee.

Details

Start:
27/06/2017
End:
28/06/2017
Event Category:
Website:
http://ais2017.fr/home/

Organizer

MabDesign
Phone:
+33 (0)4 78 02 39 88
Email:
contact@mabdesign.fr
Website:
http://www.mabdesign.fr/

Venue

Vinci – Centre International de Congrès de Tours Val-de-Loire
26 Boulevard Heurteloup
Tours, 37000 France
+ Google Map

We use cookies to give you the best experience and for advertising purposes. By accepting, you support our independent media and it's freely accessible content.